Literature DB >> 20622603

Methicillin-resistant Staphylococcus aureus in wound cultures recovered from a combat support hospital in Iraq.

Clinton K Murray1, Matthew E Griffith, Katrin Mende, Charles H Guymon, Michael W Ellis, Miriam Beckius, Wendy C Zera, Xin Yu, Edgie-Mark A Co, Wade Aldous, Duane R Hospenthal.   

Abstract

BACKGROUND: Staphylococcus aureus infections complicate care of combat-related injuries and can independently result in skin and soft-tissue infections during deployments or training. Community-associated methicillin-resistant S. aureus (CA-MRSA) strains seem to produce severe disease but retain susceptibility to many oral antimicrobials. This study characterizes 84 MRSA isolates recovered from wound cultures at a combat support hospital in Iraq.
METHODS: MRSA strains recovered from December 2007 through March 2009 were analyzed. Antimicrobial resistance testing was determined by broth microdilution and the BD Phoenix Automated Microbiology System. The genotypic pattern was analyzed by pulsed-field gel electrophoresis and polymerase chain reaction identification of resistance and virulence genes.
RESULTS: No MRSA isolates from wound cultures were resistant to vancomycin. The most active oral antistaphylococcal agents were tetracycline (95% susceptibility), trimethoprim-sulfamethoxazole (94%), and clindamycin (94%). Of agents not typically recommended as monotherapy, 98% of isolates were susceptible to rifampin, 91% to moxifloxacin, and 60% to levofloxacin. The most common pulsed-field type (PFT) was USA300 (79%). The typical staphylococcal cassette chromosome mec IV elements carrying the CA-MRSA resistance genes were present in 88% of the isolates. Panton-Valentine leukocidin virulence genes were identified in 88% of isolates, including 100% of PFT USA300. The virulence gene associated with an arginine catabolic mobile element was present in 75% of isolates, including 94% of PFT USA300.
CONCLUSION: This study is the first genotypic and phenotypic characterization of CA-MRSA recovered from wound cultures in a deployed combat hospital. The pattern noted was similar to that seen in soldiers stationed in the United States.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622603     DOI: 10.1097/TA.0b013e3181e44b57

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  5 in total

1.  Evaluation for a novel methicillin resistance (mecC) homologue in methicillin-resistant Staphylococcus aureus isolates obtained from injured military personnel.

Authors:  Anuradha Ganesan; Katrina Crawford; Katrin Mende; Clinton K Murray; Bradley Lloyd; Michael Ellis; David R Tribble; Amy C Weintrob
Journal:  J Clin Microbiol       Date:  2013-06-19       Impact factor: 5.948

2.  Lack of doxycycline antimalarial prophylaxis impact on Staphylococcus aureus tetracycline resistance.

Authors:  Katrin Mende; Miriam L Beckius; Wendy C Zera; Xin Yu; Ping Li; David R Tribble; Clinton K Murray
Journal:  Diagn Microbiol Infect Dis       Date:  2016-07-15       Impact factor: 2.803

3.  A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model.

Authors:  Andrew J Sawyer; Donna Wesolowski; Neeru Gandotra; Alexander Stojadinovic; Mina Izadjoo; Sidney Altman; Themis R Kyriakides
Journal:  Int J Pharm       Date:  2013-05-29       Impact factor: 5.875

4.  Antimicrobial drug-resistant bacteria isolated from Syrian war-injured patients, August 2011-March 2013.

Authors:  Carrie Lee Teicher; Jean-Baptiste Ronat; Rasheed M Fakhri; Mohamed Basel; Amy S Labar; Patrick Herard; Richard A Murphy
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883

5.  Staphylococcus aureus colonization of healthy military service members in the United States and Afghanistan.

Authors:  Todd J Vento; Tatjana P Calvano; David W Cole; Katrin Mende; Elizabeth A Rini; Charla C Tully; Michael L Landrum; Wendy Zera; Charles H Guymon; Xin Yu; Miriam L Beckius; Kristelle A Cheatle; Clinton K Murray
Journal:  BMC Infect Dis       Date:  2013-07-16       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.